-transparent.png){kind=logo}
Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.
Related Publications
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
April 1988,
American journal of clinical oncology,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
January 1986,
Cancer chemotherapy and pharmacology,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
December 1987,
Cancer treatment reports,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
November 1987,
Cancer treatment reports,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
May 1990,
Investigational new drugs,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
July 2006,
Investigational new drugs,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
December 1987,
Cancer treatment reports,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
May 1991,
Investigational new drugs,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
October 2009,
Investigational new drugs,
D D Von Hoff, and
S Green, and
E A Surwit, and
E V Hannigan, and
D S Alberts
August 1987,
American journal of clinical oncology,
